Compare SBET & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBET | NVAX |
|---|---|---|
| Founded | 1995 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2025 | 1996 |
| Metric | SBET | NVAX |
|---|---|---|
| Price | $5.99 | $9.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 9 |
| Target Price | ★ $18.71 | $11.33 |
| AVG Volume (30 Days) | ★ 7.0M | 4.7M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ N/A |
| Revenue | $28,055,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $105.19 | N/A |
| Revenue Next Year | $13.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 666.04 | 64.69 |
| 52 Week Low | $5.06 | $6.20 |
| 52 Week High | $40.46 | $11.85 |
| Indicator | SBET | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 48.14 |
| Support Level | $5.06 | $8.89 |
| Resistance Level | $8.20 | $10.67 |
| Average True Range (ATR) | 0.36 | 0.65 |
| MACD | 0.02 | -0.16 |
| Stochastic Oscillator | 70.08 | 24.84 |
SharpLink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.